Lonza Group AG, a Life Sciences driven chemical company, supplies active ingredients, chemical intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries. The company also offers a catalogue of organic intermediates for a range of applications, such as pharmaceuticals, agrochemicals, vitamins, food and feedstuff, dyes and pigments, adhesives and fragrances. It also manufactures specialty biocides and oleochemicals; and develops and produces specific polymer intermediates, unsaturated polyester-resins, compounds and composites. The company operates in three divisions that include Exclusive Synthesis & Biopharmaceuticals; Organic Fine & Performance Chemicals; and Polymer Intermediates. Exclusive Synthesis & Biopharmaceuticals In the area of Exclusive Synthesis and Biopharmaceuticals, Lonza is the custom manufacturing for the global life sciences companies. In addition to Lonza's traditional chemical custom manufacturing, Lonza offers microbial custom fermentation and biotransformation services. Lonza Biologics is focused on the production of therapeutic monoclonal antibodies and recombinant proteins produced by mammalian cell cultures. Exclusive chemical synthesis: Exclusive chemical synthesis engages in the process development and manufacture of intermediates and active ingredients. It is used in Life sciences industry, pharmaceuticals and animal health products. Exclusive microbial fermentation and biotransformation: Exclusive microbial fermentation and biotransformation processes development and manufactures intermediates, active ingredients and biopharmaceuticals. Its products are used Life sciences industry, pharmaceuticals and cosmetics. The company also offers L-Carnitine (L-Carnipure), which is applicable in sports nutrition, food, pharmaceuticals and feedstuffs. Exclusive microbial biopharma fermentation: Exclusive microbial biopharma fermentation engages in the process development and manufacture of therapeutic recombinant proteins and antibody fragments. It is used in pharmaceutical and biotechnology industry. Exclusive mammalian cell fermentation: Exclusive mammalian cell fermentation engages in the process development and manufacture of therapeutic monoclonal antibodies and recombinant proteins, proprietary GS-expression system, which are used in the pharmaceutical and biotechnology industry. Organic Fine & Performance Chemicals In the area of organic fine and performance chemicals, the company develops, manufactures, and sells various organic chemical intermediates applied in pharmaceuticals, agrochemicals, vitamins, food and feed, dyes, pigments, adhesives, and fragrances, as well as polymers. The sector performance chemical is mainly engaged in the development and production of biocides and oleochemicals. These core activities are supplemented by the polymer intermediates business, including additives, unsaturated polyester resins, compounds, and composites. Organic Fine Chemicals: The company offers Niacin, niacinamide, Diketene derivatives, Hydrocyanic acid derivatives, Engineering polymer additives and Meta – Metaldehyde. Its products are used in food and feedstuffs, pharmaceuticals, agrochemicals, colorants Vitamins, optical brighteners, agrochemicals, electronics, aerospace industry, and coating Snail. Performance Chemicals: The company offers microbiologically active substances, such as Quaternary ammonium, compounds, Halogenated hydantoins; and Hydantoin derivatives. It also offers Oleochemical derivatives. The company's products are used by the disinfectants for household, industrial and institutional applications, including water treatment and wood preservation; biocides for water treatment, pools and spas, and household disinfection; preservatives for personal care and household products; and food ingredients, humectants and emollients for personal care, processing aids and lubricants for polymer and textile industry, and industrial defoamers.
Synaffix BV is a clinical-stage biotechnology company based in Oss, the Netherlands, specializing in the development of antibody-drug conjugate (ADC) technology for oncology applications. Founded in 2010, the company has created proprietary platforms, including GlycoConnect and HydraSpace, which enhance the efficacy and tolerability of ADCs. GlycoConnect facilitates site-specific and stable conjugation of anti-cancer molecules by modifying naturally-occurring glycan anchor points on antibodies, while HydraSpace improves payload solubility and reduces aggregation potential. Additionally, Synaffix offers a metal-free click chemistry, applicable across the pharmaceutical, biotech, and academic sectors, which allows for the efficient development of ADCs without prior genetic modifications. The company's patent portfolio ensures protection of its innovations and resulting products through at least 2035.
Indapta Therapeutics
Series A in 2022
Indapta Therapeutics is a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers.
Codiak Biosciences
Acquisition in 2021
Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.
Affinia Therapeutics
Series B in 2021
Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.
Affinia Therapeutics
Series A in 2020
Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.
Octane Biotech
Acquisition in 2018
Octane Biotech is a medical technology company with advanced bioreactors, bioprocesses, and biomaterials for regenerative medicine solutions and bioengineering.
Micromacinazione
Acquisition in 2017
Micromacinazione S.A. is an engineering company based in Molinazzo di Monteggio, Switzerland, specializing in jet-mill technologies and micronization services for the pharmaceutical and fine chemical industries. Founded in 1970, the company offers tailored micronization solutions that enhance the performance of active pharmaceutical ingredients (APIs) and highly potent compounds, ensuring safety for personnel and the environment. Its services include research and development in pharmaceutical powder technologies, process development, and the design and manufacturing of equipment such as jet mills, glove boxes, and pneumatic conveyors. Micromacinazione's innovative approaches also focus on improving the solubility of poorly soluble drugs, catering to the evolving needs of the pharmaceutical sector. As of 2017, it operates as a subsidiary of Lonza Group Ltd.
PharmaCell
Acquisition in 2017
PharmaCell is a leading provider of cell-culturing services, specializing in cellular therapies and regenerative medicine. With GMP-certified manufacturing facilities located in Maastricht and Geleen, the company supports the development and production of commercial cell therapy products for prominent players in the industry. PharmaCell's extensive network enables it to collaborate with research and development companies, facilitating the transition of innovative products from laboratory settings to clinical applications. By focusing on unlocking the potential of cell therapies, PharmaCell aims to enhance healthcare outcomes for patients.
HansaBioMed
Acquisition in 2017
HansaBioMed OU, founded in 2007 and located in Tallinn, Estonia, focuses on research and development in the field of exosome sciences and related technologies. The company specializes in the testing and validation of cancers and neurodegenerative diseases, offering products that include proprietary platforms, kits, reagents, and equipment for exosome research. HansaBioMed is particularly known for its expertise in the purification, enrichment, and characterization of extracellular vesicles (EVs), as well as providing scalable and automated purification solutions from various biological sources. Additionally, the company offers services such as bulk and single EV characterization and biomarker assessment through advanced techniques like mass spectrometry and RNA sequencing. As of May 2017, HansaBioMed operates as a subsidiary of Lonza Group Ltd.
Exosomics Siena
Funding Round in 2017
Exosomic's mission is to develop and launch a new generation of tests for cancer screening and liquid biopsy based on analysis of circulating extracellular vesicles.
Capsugel
Acquisition in 2016
Capsugel is a global leader in delivering high-quality, innovative dosage forms and solutions to healthcare companies around the world. Our customers turn to us for the science and engineering expertise they need to bring better medicines and nutritionals to market. As the world's leading provider of empty, two-piece hard capsules and an innovator of drug delivery systems, we continue to build on our decades-long track record of quality, reliability, innovation and value creation.
ConnectedYard (pHin)
Series A in 2016
pHin combines a bluetooth and WiFi-enabled water monitor along with a mobile app to take the guesswork out of pool and hot tub care. Notifications are sent to the app when water chemistry needs rebalancing, including dosing instructions for the amount of chemicals or pre-measured, single-dose, color-coded pods to add. The pHin Mobile App also provides one-touch, on-demand access to the Pool Service on Demand network of pre-qualified pool service technicians. pHin is the first product from ConnectedYard Inc.headquartered in Campbell, Calif, which is dedicated to being the center of the connected backyard. Beginning with pool and hot tub care, our smart technology will expand to include irrigation, lighting, and every component involved in outdoor living. Our goal is to bring intelligence, simplicity and fun to the backyard.
InterHealth Nutraceuticals
Acquisition in 2016
InterHealth Nutraceuticals specializes in researching, developing, marketing and distributing proprietary branded nutraceutical ingredients. InterHealth ingredients are sold worldwide to manufacturers of dietary supplements and functional foods & beverages. The company's success is earmarked by high-quality ingredients, thorough research program, outstanding customer service and powerful co-branding marketing strategy. InterHealth has had a number of milestones along the way. Our first product, ChromeMate®, was introduced in 1987 and was just the start of our proven history. We’ve since grown into a global company, providing branded nutraceutical ingredients for some of the world’s most popular dietary supplements and food & beverage products. InterHealth continues to search for new value-added ingredients. If you would like to explore your options for high-quality ingredients for your supplemental products, please contact us at 707-751-2800. We work with our customers to create proprietary blends for their health supplements and would be happy to discuss your options.
Triangle Research Labs
Acquisition in 2016
TRL is a fast-growing hepatocyte provider with products supporting in vitro evaluation of metabolism, drug-drug interactions, drug transporter activity, toxicity of drug candidates and other applications. Triangle Research Labs has facilities based in Research Triangle Park, North Carolina (USA). Triangle Research Labs was established in 2012 and has quickly gained a reputation for high-quality products and a unique ability to understand each customer’s specific needs. This combination makes TRL a great asset to Lonza’s mission of serving customers in the bioresearch space through a culture of trust and care.
Diacon Technologies Ltd.
Acquisition in 2015
Diacon Technologies Ltd. is a supplier of anti-sapstain chemicals and delivery systems.
Zelam
Acquisition in 2015
Zelam Limited is a New Plymouth, New Zealand-based company that specializes in the research, development, production, and marketing of crop protection products. Founded in 1988, Zelam offers a range of products including fungicides, herbicides, insecticides, and foliar nutrients, which are marketed locally and internationally. Additionally, the company is involved in the manufacturing and treatment of engineered wood products, and conducts testing in its micro laboratory as well as field trials in New Zealand, Australia, and Hawaii. Zelam's products are marketed under various brand names, including TAG G2, Vixen, Taratek, and Permatek. In April 2006, Zelam Limited changed its name from Taranaki Nuchem Ltd. and is currently a subsidiary of Lonza Group Ltd.
Odyssey Thera
Venture Round in 2013
Odyssey Thera, Inc., a biopharmaceutical company, develops cellular pharmacology strategy for the identification of medicines for human diseases. It focuses on the identification and development of treatment therapies for cancer. The company was formerly known as Odyssey Pharmaceuticals. Odyssey Thera, Inc. is based in San Ramon, California.
Arch Chemicals
Acquisition in 2011
Arch Chemicals, Inc., is a global specialty chemical company based in Norwalk, Connecticut, involved in two main business segments: treatment products and performance products. Treatment products include chemicals to sanitize drinking water and swimming pools; industrial biocides, used to inhibit the growth of microorganisms in metal working fluids, paint, and other coatings; industrial wood preservatives and fire retardants; stains and lacquers to coat wood; and active ingredients and preservatives used in shampoos, cosmetics, and other personal care products. Arch's performance products include polyols used to make adhesives, sealants, and coatings; glycols for making antifreeze, cleaning products, and consumer goods; and hydrazine hydrate, used to make drugs, treat water, and blowing agents that strengthen plastics and rubbers by expanding them. In 2004 Arch sold off most of its microelectronic materials business segment, which provided slurry used by semiconductor manufacturers to remove and polish surfaces. In addition to 16 U.S. locations, Arch maintains operations in 20 other countries around the world. A spinoff of the Olin Corporation in 1999, Arch is a public company listed on the New York Stock Exchange.
Vivante GMP Solutions
Acquisition in 2010
Vivante GMP Solutions is a custom manufacturing organization dedicated to producing GMP viral-based therapeutics.
Moda Technology Partners
Acquisition in 2010
Moda Technology Partners is a commercial software company whose primary focus is addressing the growing need for effective automation and efficient regulatory compliance within pharmaceutical manufacturing. Moda's software systems leverage mobile computing technology to help pharmaceutical clients increase operational efficiency, improve quality, and reduce manufacturing costs.
AlgoNomics
Acquisition in 2009
AlgoNomics is a Belgium based biotech company providing structural bioinformatics services to develop rationally designed therapeutics in the broad field of immunotherapy. AlgoNomics owns a rich, proprietary platform for structure-based protein and peptide design. The technology platform contains innovative tools to unravel protein-protein and protein-peptide interactions. AlgoNomics' premier product is the Epibase® platform for T-cell epitope identification in different population groups, applied in the discovery of vaccines and therapeutic proteins.
Cilian AG
Corporate Round in 2009
Cilian is an emerging biotechnology company developing and marketing a novel expression system. The Company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of enzymes and therapeutic proteins. While Ciliates secrete a number of therapeutically relevant enzymes with high expression rates by nature, recombinant proteins are produced by Ciliates using genetically modified cells. Leveraging the unique capabilities of the Ciliates, the Company aims to produce proteins at an unmatched quality and price, thereby fulfilling its mission to improve human health by facilitating access to biopharmaceuticals.
Amaxa Biosystems
Acquisition in 2008
Amaxa Biosystems GmbH develops and commercializes gene transfer technologies and products. The company offers Nucleofector Technology, a transfection solution which enables the transfer of various substrates, such as DNA, RNA, or peptides into cells. It also offers transfection services; HiFect transfection reagent, the transfection reagent for standard cell lines; antibiotics for the treatment and prevention of mycoplasma and other microbial contaminants; Expression Vectors for the expression of bright fluorescent proteins and individual customer constructs in mammalian cells; and peptide Nucleofection and transfection control solutions. Amaxa Biosystems offers its solutions in Canada, China, Croatia, Greece, Hong Kong, Indonesia, Japan, Korea, Malaysia, Mexico, Portugal, Singapore, Spain, Taiwan, and Turkey. The company was founded in 1998 and is based in Cologne, Germany. As of July 2, 2008, Amaxa Biosystems GmbH operates as a subsidiary of Lonza Group AG.
SAM Electron Technologies
Acquisition in 2007
SAM Electron Technologies develops an electrochemical cerium-based oxidation technology.
UCB-Bioproducts
Acquisition in 2006
UCB-Bioproducts provides chemical peptide manufacturing services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.